Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,500 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 6 July 2020) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

 (PDF, 3MB, 206 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website

 

 

Export 5 results:
Author Title [ Type(Desc)] Year
Filters: Author is Rigney, U.  [Clear All Filters]
Journal Article
A. Bakhai, Rigney, U., Hollis, S., and Emmas, C., Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population, Pharmacoepidemiol Drug Saf, vol. 21, pp. 485-93, 2012.
J. Wilding, Bailey, C., Rigney, U., Blak, B., Kok, M., and Emmas, C., Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up, Prim Care Diabetes, vol. 11, pp. 437-444, 2017.
P. H. Wilding J, Rigney, U., Blak, B. T., Nolan, S. T., Fenici, P., and Medina, J., Glycaemic, weight, and blood pressure changes associated with early versus later treatment intensification with dapagliflozin in United Kingdom primary care patients with type 2 diabetes mellitus, Diabetes Res Clin Pract, p. 107791, 2019.
J. Wilding, Bailey, C., Rigney, U., Blak, B., Beekman, W., and Emmas, C., Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study, Diabetes Ther, vol. 7, pp. 695-711, 2016.
B. T. Blak, Rigney, U., Sternhufvud, C., Davis, J., and Hammar, N., Weight change and healthcare resource use in English patients with type 2 diabetes mellitus initiating a new diabetes medication class, Int J Clin Pract, vol. 70, pp. 45-55, 2016.
[Page last reviewed 6 July 2020]